Goldman Sachs Group Inc Metacrine, Inc. Transaction History

Goldman Sachs Group Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.36 - $0.63 $5,667 - $9,918	-15,744 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.43 - $0.7 $83,717 - $136,283	-194,691 Reduced 92.52%	15,744 $10,000
Q4 2021 Feb 14, 2022	BUY	$0.64 - $3.83 $124,604 - $745,678	194,694 Added 1236.86%	210,435 $142,000
Q3 2021 Nov 10, 2021	BUY	$2.61 - $3.84 $41,084 - $60,445	15,741 New	15,741 $54,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.